Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma

Biologicals

Volumn 35, Issue 4, 2007, Pages 349-353

  Burnouf, Thierry ^a   Goubran, Hadi Alphonse ^b   Radosevich, Miryana ^a   Sayed, Makram A ^c   Gorgy, George ^d   El Ekiaby, Magdy ^d  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

^b CAIRO UNIVERSITY   (Egypt)

^c FAYOUM UNIVERSITY   (Egypt)

^d Shabrawishi Hospital Blood Bank   (Egypt)

Author keywords

Alpha 2 antiplasmin; Plasma; SERPINF2; Solvent detergent; Virus

Indexed keywords

ALPHA 2 ANTIPLASMIN; DETERGENT; SOLVENT; SOYBEAN OIL; TRIBUTYL PHOSPHATE; TRITON X 100; TRITON X 45; TYLOXAPOL; UNCLASSIFIED DRUG;

ARTICLE; CENTRIFUGATION; CHROMATOGRAPHY; CONTROLLED STUDY; EXTRACTION; FIBRINOLYSIS; HUMAN; PLASMA; PRIORITY JOURNAL; TRANSFUSION; VIRUS INACTIVATION;

ANTIPLASMIN; BLOOD TRANSFUSION; DETERGENTS; HUMANS; OCTOXYNOL; PHOSPHORIC ACID ESTERS; PLASMA; SOLVENTS; VIRUS INACTIVATION;

GLYCINE MAX;

EID: 35248876717     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2007.03.002     Document Type: Article

References (36)

1. Horowitz B., Bonomo R., Prince A.M., Chin S.N., Brotman B., and Shulman R.W. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 79 (1992) 826-831
2. WHO. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. www.WHO.int. Geneva; 2003. p. 1-72.
3. Horowitz B., Prince A.M., Horowitz M.S., and Watklevicz C. Viral safety of solvent-detergent treated blood products. Dev Biol Stand 81 (1993) 147-161
4. Horowitz B., Lazo A., Grossberg H., Page G., Lippin A., and Swan G. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 74 Suppl. 1 (1998) 203-206
5. Burnouf T., and Radosevich M. Reducing the risk of infection from plasma products: Specific preventative strategies. Blood Rev 14 (2000) 94-110
6. Piquet Y., Janvier G., Selosse P., Doutremepuich C., Jouneau J., Nicolle G., et al. Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang 63 (1992) 251-256
7. Hellstern P., Sachse H., Schwinn H., and Oberfrank K. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 63 (1992) 178-185
8. Haubelt H., Blome M., Kiessling A.H., Isgro F., Bach J., Saggau W., et al. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 82 (2002) 9-14
9. Beeck H., and Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang 74 Suppl. 1 (1998) 219-223
10. Doyle S., O'Brien P., Murphy K., Fleming C., and O'Donnell J. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 14 (2003) 283-287
11. Mast A.E., Stadanlick J.E., Lockett J.M., and Dietzen D.J. Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood 94 (1999) 3922-3927
12. Burnouf T., Goubran H.A., Radosevich M., Sayed M.A., Gorgy G., and El-Ekiaby M. A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system. Transfusion 46 (2006) 2100-2108
13. Dzik W.H., Arkin C.F., Jenkins R.L., and Stump D.C. Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator. Blood 71 (1988) 1090-1095
14. Burnouf T., Goubran H.A., Radosevich M., Sayed M.A., Gorgy G., and El-Ekiaby M. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Vox Sang 91 (2006) 56-62
15. de Jonge J., Groenland T.H., Metselaar H.J., IJzermans J.N., van Vliet H.H., Visser L., et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg 94 (2002) 1127-1131
16. Nifong T.P., Light J., and Wenk R.E. Coagulant stability and sterility of thawed S/D-treated plasma. Transfusion 42 (2002) 1581-1584
17. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 11 (2004) 346-350
18. Heger A., Romisch J., and Svae T.E. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfus Apher Sci 35 (2006) 223-233
19. Solheim B.G., and Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 35 (2006) 83-90
20. Clason S.B., Meijer P., Kluft C., and Ersdal E. Specific determination of plasmin inhibitor activity in plasma: documentation of specificity of manual and automated procedures. Blood Coagul Fibrinolysis 10 (1999) 487-494
21. van Gent D., Sharp P., Morgan K., and Kalsheker N. Serpins: structure, function and molecular evolution. Int J Biochem Cell Biol 35 (2003) 1536-1547
22. Law R.H., Zhang Q., McGowan S., Buckle A.M., Silverman G.A., Wong W., et al. An overview of the serpin superfamily. Genome Biol 7 (2006) 216
23. Huntington J.A., Read R.J., and Carrell R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407 (2000) 923-926
24. Loebermann H., Tokuoka R., Deisenhofer J., and Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 177 (1984) 531-557
25. Potempa J., Korzus E., and Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 269 (1994) 15957-15960
26. Mast A.E., Enghild J.J., and Salvesen G. Conformation of the reactive site loop of alpha 1-proteinase inhibitor probed by limited proteolysis. Biochemistry 31 (1992) 2720-2728
27. Gils A., and Declerck P.J. Modulation of plasminogen activator inhibitor 1 by Triton X-100-identification of two consecutive conformational transitions. Thromb Haemost 80 (1998) 286-291
28. Andreasen P.A., Egelund R., Jensen S., and Rodenburg K.W. Solvent effects on activity and conformation of plasminogen activator inhibitor-1. Thromb Haemost 81 (1999) 407-414
29. Gils A., Pedersen K.E., Skottrup P., Christensen A., Naessens D., Deinum J., et al. Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb Haemost 90 (2003) 206-217
30. Preissner K.T. Self-association of antithrombin III relates to multimer formation of thrombin-antithrombin III complexes. Thromb Haemost 69 (1993) 422-429
31. Hellstern P., and Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 107 Suppl. 1 (2002) S3-S8
32. Solheim B.G., and Hellstern P. Composition, efficacy, and safety of S/D-treated plasma. Transfusion 43 (2003) 1176-1178 [author reply 78]
33. Salge-Bartels U., Breitner-Ruddock S., Hunfeld A., Seitz R., and Heiden M. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe?. Transfus Med 16 (2006) 266-275
34. Kolarich D., Turecek P.L., Weber A., Mitterer A., Graninger M., Matthiessen P., et al. Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy. Transfusion 46 (2006) 1959-1977
35. Doyle J.W., Johnson G.L., Eshhar N., and Hammond D. The use of rabbit polyclonal antibodies to assess neoantigenicity following viral reduction of an alpha-1-proteinase inhibitor preparation. Biologicals 34 (2006) 199-207
36. Chen S.X., Hammond D.J., Lang J.M., and Lebing W.R. Purification of alpha 1 proteinase inhibitor from human plasma fraction IV-1 by ion exchange chromatography. Vox Sang 74 (1998) 232-241